Sernova Corp (SEOVF)

$0.15 +0.00 (3.07%)
Market Cap 49.63M
Revenue (ttm) 0.00
Net Income (ttm) -23.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,200
Avg Vol 38,478
Day's Range N/A - N/A
Shares Out 328.49M
Stochastic %K 89%
Beta 1.16
Analysts Strong Buy
Price Target $0.57

Company Profile

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. The comoany was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February...

Industry: Biotechnology
Sector: Healthcare
Phone: 519 858 5184
Fax: 519 858 5099
Address:
700 Collip Circle, Suite 114, London, Canada
3D_STOCK_TRADING
3D_STOCK_TRADING Nov. 9 at 2:18 AM
$SEOVF this will break to the upside soon. I am in for the long run.
1 · Reply
marvessa
marvessa Oct. 29 at 11:23 AM
$SEOVF very frustrating invest
0 · Reply
newsfile_corp
newsfile_corp Oct. 1 at 11:00 AM
https://nfne.ws/268665 $SEOVF $SVA.TSX #Chemicals #Biotechnology #Financing #OTC #OTCMarkets #OTCStocks #TSX #Investing
0 · Reply
Dude1234
Dude1234 Sep. 23 at 12:26 PM
$SEOVF 23 Sept 2025 Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors “I am thrilled to join Sernova at such an exciting moment in its journey,” said Mr. Brooks. “The Cell Pouch Bio-hybrid Organ holds great potential for patients with T1D, and the integration of novel immunotherapies like tegoprubart could significantly improve the durability and effectiveness of islet cell transplantation. I look forward to working with the leadership team and board to help guide Sernova as we seek to provide T1D patients with a viable functional cure.”
0 · Reply
GoodTidings
GoodTidings Aug. 30 at 10:27 AM
$SEOVF Excitement about Sernova is over... They are too late... Their product or whatever it was should have come out next year not in another decade... There are other exciting developments with that time frame which are far better like stem cell reviving insuline production in the existing disfunctional organ... Time matters... 🤔🤔🤔
0 · Reply
Dude1234
Dude1234 Jul. 25 at 2:37 PM
$SEOVF Leede Financial Inc. analyst Dr. Douglas W. Loe maintained a Speculative Buy rating on Sernova with a CA$1.50 price target, representing 1,000% upside from the share price at the time of the report of CA$0.15 GLTA.
1 · Reply
StreetwiseReports
StreetwiseReports Jul. 15 at 9:34 PM
Biotech Partnership to Revolutionize Diabetes Treatment https://ow.ly/Bjry50Wqfnh Sernova Biotherapeutics Inc. announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D). $SVA.V $SEOVF
1 · Reply
StreetwiseReports
StreetwiseReports Jul. 14 at 8:46 PM
Biotech Enters Agreement with Co. Behind Tegoprubart https://ow.ly/kQuu50WpyHs Sernova Biotherapeutics Inc. likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. $SVA.V $SEOVF
0 · Reply
NoMoreHaircuts
NoMoreHaircuts Jul. 12 at 2:57 AM
$SEOVF Despite the tiny market cap and struggle for cash, Sernova has built a good history of clinical trials, even if the trials have had very limited enrolment. Their future plans do seem consistent with a 5-year timeline to roll out a commercial product. My main question is whether a company like SANA could also roll out a commercial product in 5 years that doesn't require any immunosuppressants, whatsoever. I'm bullish on Sernova as a long-term , but more bullish on SANA.
1 · Reply
StreetwiseReports
StreetwiseReports Jul. 10 at 7:54 PM
Canadian Biotech Targets Massive Cell Technology Gains https://ow.ly/UBig50Wo04u Sernova Biotherapeutics Inc. recently announced a partnership with Eledon Pharmaceuticals Inc. to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy. $SVA.V $SEOVF $ELDN
0 · Reply
Latest News on SEOVF
No data available.
3D_STOCK_TRADING
3D_STOCK_TRADING Nov. 9 at 2:18 AM
$SEOVF this will break to the upside soon. I am in for the long run.
1 · Reply
marvessa
marvessa Oct. 29 at 11:23 AM
$SEOVF very frustrating invest
0 · Reply
newsfile_corp
newsfile_corp Oct. 1 at 11:00 AM
https://nfne.ws/268665 $SEOVF $SVA.TSX #Chemicals #Biotechnology #Financing #OTC #OTCMarkets #OTCStocks #TSX #Investing
0 · Reply
Dude1234
Dude1234 Sep. 23 at 12:26 PM
$SEOVF 23 Sept 2025 Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors “I am thrilled to join Sernova at such an exciting moment in its journey,” said Mr. Brooks. “The Cell Pouch Bio-hybrid Organ holds great potential for patients with T1D, and the integration of novel immunotherapies like tegoprubart could significantly improve the durability and effectiveness of islet cell transplantation. I look forward to working with the leadership team and board to help guide Sernova as we seek to provide T1D patients with a viable functional cure.”
0 · Reply
GoodTidings
GoodTidings Aug. 30 at 10:27 AM
$SEOVF Excitement about Sernova is over... They are too late... Their product or whatever it was should have come out next year not in another decade... There are other exciting developments with that time frame which are far better like stem cell reviving insuline production in the existing disfunctional organ... Time matters... 🤔🤔🤔
0 · Reply
Dude1234
Dude1234 Jul. 25 at 2:37 PM
$SEOVF Leede Financial Inc. analyst Dr. Douglas W. Loe maintained a Speculative Buy rating on Sernova with a CA$1.50 price target, representing 1,000% upside from the share price at the time of the report of CA$0.15 GLTA.
1 · Reply
StreetwiseReports
StreetwiseReports Jul. 15 at 9:34 PM
Biotech Partnership to Revolutionize Diabetes Treatment https://ow.ly/Bjry50Wqfnh Sernova Biotherapeutics Inc. announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D). $SVA.V $SEOVF
1 · Reply
StreetwiseReports
StreetwiseReports Jul. 14 at 8:46 PM
Biotech Enters Agreement with Co. Behind Tegoprubart https://ow.ly/kQuu50WpyHs Sernova Biotherapeutics Inc. likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. $SVA.V $SEOVF
0 · Reply
NoMoreHaircuts
NoMoreHaircuts Jul. 12 at 2:57 AM
$SEOVF Despite the tiny market cap and struggle for cash, Sernova has built a good history of clinical trials, even if the trials have had very limited enrolment. Their future plans do seem consistent with a 5-year timeline to roll out a commercial product. My main question is whether a company like SANA could also roll out a commercial product in 5 years that doesn't require any immunosuppressants, whatsoever. I'm bullish on Sernova as a long-term , but more bullish on SANA.
1 · Reply
StreetwiseReports
StreetwiseReports Jul. 10 at 7:54 PM
Canadian Biotech Targets Massive Cell Technology Gains https://ow.ly/UBig50Wo04u Sernova Biotherapeutics Inc. recently announced a partnership with Eledon Pharmaceuticals Inc. to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy. $SVA.V $SEOVF $ELDN
0 · Reply
Michl2000
Michl2000 Jul. 9 at 1:04 PM
$SEOVF 🥳👍
0 · Reply
Michl2000
Michl2000 Jul. 7 at 4:14 PM
$SEOVF still waiting 🥳
1 · Reply
StreetwiseReports
StreetwiseReports Jun. 26 at 7:17 PM
Analyst Has Confidence in Biotech's Path https://ow.ly/ikGH50Wh3RY Vertex Pharmaceuticals Inc.'s updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note. $VRTX $SVA.V $SEOVF Sernova Biotherapeutics Inc.
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 23 at 3:54 PM
Biotech Boasts Compelling Pipeline https://ow.ly/q2Uo50WeUgs Sernova Biotherapeutics Inc. is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report. $SVA.V $SEOVF
0 · Reply
Michl2000
Michl2000 Jun. 13 at 4:57 PM
$SEOVF waiting for news
3 · Reply
StreetwiseReports
StreetwiseReports Jun. 10 at 5:41 PM
Biotech Firm Unveils Diabetes Breakthrough in Canada https://ow.ly/UlvH50W7emi Sernova Biotherapeutics Inc. advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes. $SVA.V $SEOVF
1 · Reply
Michl2000
Michl2000 May. 27 at 4:45 PM
$SEOVF R.I.P. Sernova
0 · Reply
Dude1234
Dude1234 May. 23 at 11:48 AM
$SEOVF Pretty Decent new Scientific Advisory Board. https://sernova.com/press_releases/sernova-biotherapeutics-appoints-world-class-clinical-advisory-board-to-support-development-of-cell-pouch-bio-hybrid-organ-as-functional-cure-for-type-1-diabetes/
0 · Reply
Dude1234
Dude1234 May. 20 at 1:55 PM
$SEOVF https://www.technologynetworks.com/tn/online-events/innovations-in-biopharma-2025-395670?section=overview
0 · Reply
Dude1234
Dude1234 May. 19 at 4:22 PM
$SEOVF 21 May. This should be interesting. GLTA.
0 · Reply
StreetwiseReports
StreetwiseReports May. 15 at 9:23 PM
Interim Data From TID Trial Are Positive: https://ow.ly/VA6350VTyyc Sernova Biotherapeutics Inc.'s regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit. $SVA.V $SEOVF
0 · Reply